Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
Sponsor: Avistone Biotechnology Co., Ltd.
Summary
This is a first-in-human (FIH) Phase I/II, multi-center, open-label, study of ANS02, in patients with advanced NSCLC. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS02 as monotherapy.
Official title: A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS02 in Participants With EGFR Mutation-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
294
Start Date
2026-06-09
Completion Date
2029-10-30
Last Updated
2026-05-22
Healthy Volunteers
No
Conditions
Interventions
ANS02
4 dose levels would be explored during the study.
Locations (4)
Research Site
Fairfax, Virginia, United States
Research Site
Guangzhou, Guangdong, China
Research Site
Harbin, Heilongjiang, China
Research Site
Zhengzhou, Henan, China